We thank Drs Mikhail and Cope for pointing out the importance of the potential drug interactions between statins and protease inhibitors, particularly ritonavir, which is a potent inhibitor of cytochrome (CY) P3A4. However, in addition to the 2 cases of rhabdomyolysis due to probable interaction with simvastatin and ritonavir that were referenced, an additional case of rhabdomyolysis due to atorvastatin and delavirdine has been reported in an individual receiving 20 mg of atorvastatin.1 The most common clinical abnormality associated with ritonavir use is a marked elevation in triglyceride levels that cannot be controlled by statin monotherapy, and clearly this patient population merits further investigation. A recent review of the new lopinavir-ritonavir formulation notes that there were no clinically significant interactions with pravastatin, which is not metabolized through the CYP3A4 system, nor were there expected to be interactions with fluvastatin, which also is not metabolized through the CYP3A4 system.2 In regard to the recommendation in the article not to prescribe high-dose statin therapy for patients with renal insufficiency, we disagree with Drs Mikhail and Cope that this recommendation should not apply to atorvastatin. Primary care physicians were cautioned not to use maximal-dose statins in patients with renal insufficiency because rhabdomyolysis in this patient population is much more likely to result in acute renal failure compared with individuals with normal renal function. Currently, there are no published prospective, long-term studies that have used 80 mg of atorvastatin in patients with renal insufficiency, with the only 2 published trials limiting the dose to 40 mg.3,4
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
* * SCHEDULED MAINTENANCE * *
Our websites may be periodically unavailable between midnight and 04:00 ET Thursday, July 10th, for regularly scheduled maintenance.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 6
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
Users' Guides to the Medical Literature
Statin Dosing and LDL Levels
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.